spacer
home > pmps > winter 2003 > taking nasal drug delivery seriously: examples of pain-free and user-friendly alternative
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Taking Nasal Drug Delivery Seriously: Examples of Pain-Free and User-Friendly Alternative

Nasal Drug Delivery

Nasal sprays and drops have been used extensively for decades to prevent and treat ailments such as nasal congestion and allergic rhinitis. More recently the nasal route has been recognised as a convenient, reliable and non-invasive alternative to the parenteral route for the systemic administration of several compounds. Using this delivery route, nasal mucosa acts as a portal of entry for drugs into the bloodstream and potentially has a similar pharmaco-kinetic profile as drugs delivered intravenously. In particular, research has been exploring the direct transport of drugs from the nasal cavity to the central nervous system (CNS).

Drug development in the 21st century will not only rely on innovative new compounds and sophisticated formulations, but also on the efficiency, safety and comfort of the dispensing systems. The ideal 'nasal spray drug delivery device' should have optimum performance, (accurate and reproducible dose, narrow spray droplet size distribution; and support patient compliance, thus contributing to the reduction in global health expenditure. In addition, patients are now behaving more like consumers, and key issues such as device convenience, ease-of-use, attractiveness of the design and style, will reinforce brand recognition and loyalty, which will ultimately contribute to product success.

Nasal devices have progressively evolved from pipettes and droppers through to spraying devices such as squeeze bottles (which do not control the dose of drug delivered or the quality of the spray), towards metering spray pumps and valves and unit-dose nasal spray devices.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pierre Carlotti, Marketing Director at Valois Pharmaceutical Division

Pierre Carlotti holds a Masters degree in Biology and a degree in Business Administration. Before taking the position of Marketing Director at Valois, he was Business Development Manager for a line of drug delivery devices. Before joining Valois, Pierre held various positions in sales, business development and marketing at West Pharmaceutical Services and Sanofi-Synthelabo.

spacer
Pierre Carlotti
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement